Evergreen Capital Management LLC Sells 940 Shares of Amgen Inc. (NASDAQ:AMGN)

Evergreen Capital Management LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,099 shares of the medical research company's stock after selling 940 shares during the quarter. Evergreen Capital Management LLC's holdings in Amgen were worth $2,111,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Blossom Wealth Management lifted its position in shares of Amgen by 3.5% in the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after purchasing an additional 37 shares during the period. Zullo Investment Group Inc. lifted its holdings in Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock valued at $356,000 after buying an additional 37 shares during the period. Trillium Asset Management LLC boosted its position in Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock valued at $237,000 after acquiring an additional 37 shares during the last quarter. Evermay Wealth Management LLC grew its holdings in Amgen by 1.5% during the 4th quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock worth $691,000 after acquiring an additional 38 shares during the period. Finally, Great Lakes Retirement Inc. lifted its stake in shares of Amgen by 0.4% in the 4th quarter. Great Lakes Retirement Inc. now owns 10,220 shares of the medical research company's stock valued at $2,664,000 after purchasing an additional 38 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $0.26 during midday trading on Wednesday, hitting $278.66. The company's stock had a trading volume of 691,480 shares, compared to its average volume of 2,781,276. The stock has a fifty day moving average price of $302.25 and a 200 day moving average price of $293.45. The firm has a market capitalization of $149.82 billion, a price-to-earnings ratio of 36.91, a P/E/G ratio of 2.63 and a beta of 0.59. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Cantor Fitzgerald began coverage on shares of Amgen in a research note on Tuesday. They issued a "neutral" rating and a $305.00 price objective for the company. Citigroup reissued a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Morgan Stanley raised their price target on shares of Amgen from $328.00 to $330.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 9th. Finally, Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $310.57.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock valued at $20,644,335 in the last three months. Company insiders own 0.69% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.